The Sidney Kimmel Comprehensive Cancer Center (SKCCC) Mass Spectrometry Core uses mass spectrometry coupled to one (ID) and two (2D) dimensional separations by column chromatography or gel electrophoresis to identify, quantify or characterize proteins and their post-translational modifications, that are expressed in well characterized protein fractions from cancerous cells, tissues or body fluids. Techniques such as difference gel electrophoresis (DIGE), isobaric tag for relative and absolute quantitation (iTRAQ), tandem mass tags (TMT) and stable isotope labeling of amino acids in cell culture (SILAC) as well as non-labeling methods (MudPIT, multi-dimensional protein identification technology) are available for quantifying relative differences in protein expression and post-translational modifications, such as acetylation, glycosylation, phosphorylation, nitrosation, ubiquitination and novel cleavage sites. Also available are Core developed methods to characterize post-translational modifications, such as LCMS methods to accurately determine the mass of intact proteins, a selective fluorescent labeling of cysteines to detect oxidized or nitrosated cysteines, or enrichment strategies to map phosphorylation sites. This Core is a part of larger institutional resource and provides a Proteomics Specialist to assist Center investigators and their staff in preparing and analyzing their samples or in using the Core's multi-user equipment. Through the Proteomics Specialist, the Center investigators have access to all the staff and expertise in the Johns Hopkins School of Medicine Mass Spectrometry and Proteomics Facility. Lay: The Mass Spectrometry Core not only identifies and quantifies proteins of interest to center investigators, but also identifies and quantifies the protein modifications and the proteins with which they interact and by which they are regulated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661017
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$72,567
Indirect Cost
$27,863
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Qiu, Xiang; Kumari, Gita; Gerasimova, Tatiana et al. (2018) Sequential Enhancer Sequestration Dysregulates Recombination Center Formation at the IgH Locus. Mol Cell 70:21-33.e6
Haffner, Michael C; Taheri, Diana; Luidy-Imada, Eddie et al. (2018) Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proc Natl Acad Sci U S A 115:E8580-E8582
Nauman, Gina; Gray, Javaughn Corey; Parkinson, Rose et al. (2018) Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel) 7:
Ransome, Yusuf; Thurber, Katherine A; Swen, Melody et al. (2018) Social capital and HIV/AIDS in the United States: Knowledge, gaps, and future directions. SSM Popul Health 5:73-85
Kagohara, Luciane T; Stein-O'Brien, Genevieve L; Kelley, Dylan et al. (2018) Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics 17:49-63
De Silva, Ravindra A; Kumar, Dhiraj; Lisok, Ala et al. (2018) Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. Mol Pharm 15:3946-3952
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Rev Mol Diagn 18:155-163
Afsari, Bahman; Guo, Theresa; Considine, Michael et al. (2018) Splice Expression Variation Analysis (SEVA) for inter-tumor heterogeneity of gene isoform usage in cancer. Bioinformatics 34:1859-1867
Zarif, Jelani C; Chalfin, Heather J; Pierorazio, Phillip M et al. (2018) Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. J Clin Urol 11:226-228
Rowe, Steven P; Luber, Brandon; Makell, Monique et al. (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661-1672

Showing the most recent 10 out of 2393 publications